Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články
PubMed
35502609
DOI
10.1111/ejh.13784
Knihovny.cz E-zdroje
- Klíčová slova
- DLBCL, polatuzumab vedotin, real world,
- MeSH
- bendamustin hydrochlorid MeSH
- chimerické antigenní receptory * MeSH
- difúzní velkobuněčný B-lymfom * diagnóza farmakoterapie MeSH
- imunokonjugáty * MeSH
- lidé MeSH
- monoklonální protilátky MeSH
- nehodgkinský lymfom * farmakoterapie MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky MeSH
- rituximab MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- Názvy látek
- bendamustin hydrochlorid MeSH
- chimerické antigenní receptory * MeSH
- imunokonjugáty * MeSH
- monoklonální protilátky MeSH
- polatuzumab vedotin MeSH Prohlížeč
- rituximab MeSH
OBJECTIVES: Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. METHODS: We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). RESULTS: Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. CONCLUSION: Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.
Zobrazit více v PubMed
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209-216.
Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-715.
Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254-e265.
Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell Lymphoma. J Clin Oncol. 2020;38(2):155-165.
Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab Vedotin plus Bendamustine and rituximab in relapsed/refractory diffuse large B-cell Lymphoma: updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension. Blood. 2020;136(Supplement 1):17-19.
Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5(13):2707-2716.
Segman Y, Ribakovsky E, Avigdor A, et al. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leuk Lymphoma. 2020;1-7:118-124.
Dimou M, Papageorgiou SG, Stavroyianni N, et al. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol. 2021;39(3):336-348.
Smith SD, Lopedote P, Samara Y, et al. Polatuzumab Vedotin for relapsed/refractory aggressive B-cell Lymphoma: a multicenter post-marketing analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):170-175.
Northend M, Wilson W, Osborne W, et al. Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma. Blood Adv. 2022;12. doi: 10.1182/bloodadvances.2021005953
Cheson BD, Fisher RI, Barrington SF, et al. Eastern cooperative oncology G, European mantle cell Lymphoma C, Italian Lymphoma F, European organisation for R, treatment of cancer/Dutch Hemato-oncology G, Grupo Espanol de Medula O, German high-grade Lymphoma study G, German Hodgkin's study G, Japanese Lymphorra study G, Lymphoma study a, group NCT, Nordic Lymphoma study G, southwest oncology G, United Kingdom National Cancer Research I. recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
ClinicalTrials.gov
NCT03199066
